Cue Biopharma director granted 1,626 stock options

Cue Biopharma director Viola Mong received a new stock option grant as part of her compensation.

Rhea-AI Filing Summary

Cue Biopharma director Viola Mong received a new stock option grant as part of her compensation. She was awarded options covering 1,626 shares of common stock at an exercise price of $21.90 per share. These options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments, aligning her incentives with the company’s long-term performance.

Insider Trade Summary

Grant/Award: 1,626 shares

Grant/Award 1 txn

Insider Meehan Viola Mong

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,626	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,626 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

Key Figures

Option grant size: 1,626 shares Exercise price: $21.90 per share Post-grant derivative holdings: 1,626 options +2 more

5 metrics

Option grant size 1,626 shares Underlying common stock for new option award

Exercise price $21.90 per share Strike price of stock option grant

Post-grant derivative holdings 1,626 options Total options held after this transaction

Expiration date May 29, 2036 Option grant expiration

Vesting schedule 3 years One-third after one year, remainder in eight quarterly installments

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 21.9000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"scheduled to vest over three years with one-third vesting on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cue Biopharma (CUE) report for Viola Mong?

Cue Biopharma reported that director Viola Mong received a stock option grant for 1,626 shares. The options allow her to buy common stock at a fixed exercise price as part of her equity-based compensation package, aligning her interests with long-term shareholder value.

How many Cue Biopharma (CUE) shares are covered by Viola Mong’s new options?

The new stock option grant to director Viola Mong covers 1,626 underlying shares of Cue Biopharma common stock. This number represents the maximum shares she may acquire through exercise, subject to the vesting schedule set out in the award’s terms.

What is the exercise price of Viola Mong’s Cue Biopharma (CUE) stock options?

The stock options granted to director Viola Mong have an exercise price of $21.90 per share. This means she can buy Cue Biopharma common stock at that fixed price once the options vest, regardless of the market price at that time.

How do Viola Mong’s Cue Biopharma (CUE) options vest over time?

The options granted to Viola Mong vest over three years. One-third vests on the one-year anniversary of the grant date, and the remaining balance vests in eight equal quarterly installments, encouraging continued board service and long-term alignment with company performance.

When do Viola Mong’s Cue Biopharma (CUE) stock options expire?

The stock options granted to director Viola Mong expire on May 29, 2036. After this expiration date, any unexercised portion of the 1,626-share award will lapse, and she will no longer be able to purchase shares under this particular option grant.

Is Viola Mong’s Cue Biopharma (CUE) option grant a market purchase or a compensation award?

The transaction is a compensation-related award, not a market purchase. It is coded as a grant or other acquisition, indicating Cue Biopharma issued the options to director Viola Mong at no cost as part of her overall director compensation package.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 08:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meehan Viola Mong

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.9	05/30/2026		A		1,626		(1)	05/29/2036	Common Stock	1,626	$0	1,626	D

Explanation of Responses:

1. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.

	/s/ Michael Meluzio, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)